Trials / Completed
CompletedNCT03835975
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ≥65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 875 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 13vPnC | Pneumococcal conjugate vaccine |
| BIOLOGICAL | PPSV23 | Pneumococcal polysaccharide vaccine |
| BIOLOGICAL | 20vPnC | Pneumococcal conjugate vaccine |
Timeline
- Start date
- 2019-02-12
- Primary completion
- 2020-02-12
- Completion
- 2020-02-12
- First posted
- 2019-02-11
- Last updated
- 2021-02-21
- Results posted
- 2021-02-21
Locations
42 sites across 2 countries: United States, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03835975. Inclusion in this directory is not an endorsement.